# Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study

> **NCT05096832** · PHASE3 · COMPLETED · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 10381 (actual)

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
- **BIOLOGICAL:** Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

## Key facts

- **NCT ID:** NCT05096832
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-03
- **Primary completion:** 2022-02-18
- **Final completion:** 2023-04-14
- **Target enrollment:** 10381 (ACTUAL)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096832, "Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05096832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*